Quick Evidence Summary
| Evidence type | Current status |
|---|---|
| Peer-reviewed human clinical trials | Yes, including the trials that supported its FDA-approved drug status |
| FDA drug-approval history | Previously approved (brand name Geref) for pediatric growth hormone deficiency |
| Adult research | Also studied in published research on adult-onset growth hormone insufficiency |
| Mechanistic plausibility | Strong, characterized through the trials supporting the original approval |
| Current regulatory status | No longer an approved drug; sold as a research chemical, not currently prescribed as it once was |
What Sermorelin Is
Sermorelin is the first 29 amino acids of human growth hormone-releasing hormone (GHRH), the shortest fragment that has been shown to retain full biological activity at the GHRH receptor. Rather than being a synthetic analog built to loosely mimic a natural pathway, it's a truncated version of a hormone the body already produces, which is part of why its research history looks different from most peptides discussed elsewhere on this site.
Human Evidence
This is where Sermorelin genuinely stands apart from most other compounds in this Evidence Reviews cluster. A version of Sermorelin was previously marketed as an FDA-approved prescription drug under the brand name Geref, indicated for pediatric growth hormone deficiency. Reaching that approval meant going through the formal clinical trial process the FDA requires for a new drug, including trials supporting both safety and efficacy for that pediatric indication. That is a categorically different evidentiary bar than a compound that has only been studied in animals or described anecdotally online.
Sermorelin's human research history doesn't stop at the pediatric approval, either. It has also been studied in published research in the context of adult-onset growth hormone insufficiency, extending its evidence base beyond the original Geref indication.
Why this matters: because of this drug-approval history, Sermorelin represents genuinely different evidentiary territory than most other peptides discussed on this site. Rather than being extrapolated primarily from animal studies or anecdotal reports, its core mechanism and basic safety profile in humans were established through the same regulatory pathway used for approved medications.
Preclinical (Animal) Evidence
As with most peptides that eventually reach human testing, Sermorelin's development also included preclinical work characterizing its activity at the GHRH receptor and its downstream effect on growth hormone release before human trials began. In Sermorelin's case, though, that animal work was a stepping stone toward the human trials that supported its original approval, not the endpoint of its evidence base the way it is for many research-chemical peptides that have never advanced past preclinical study.
Mechanistic Rationale
Sermorelin binds the GHRH receptor, triggering a growth hormone pulse through a pathway that was well characterized in the trials that supported its original approval. Because that mechanism was studied specifically in humans, as part of the approval process, it isn't a hypothesis extrapolated from animal models the way it is for many other peptides. It's a pathway that was directly demonstrated in the population it was approved to treat.
Why the Evidence Picture Changed After Discontinuation
It's worth being precise about a nuance here, because it's easy to overstate Sermorelin's current status based on its past. Geref was discontinued from the market for commercial reasons, not because of a safety failure discovered after approval. But discontinuation still changed the evidence picture for anyone buying Sermorelin today: the product actually being sold now is a research chemical, not the original regulated pharmaceutical. Dosing, purity, and formulation of current research-chemical Sermorelin are not regulated the way Geref was.
That distinction matters. Sermorelin the molecule has real human trial history behind it. That does not automatically mean every claim made about it today, particularly by research-chemical vendors selling it outside the discontinued drug context, is equally well-supported. There's a meaningful difference between "this molecule has a genuine approval history" and "every current research-chemical Sermorelin product on the market is equivalent to that original approved drug." Both things are true at once, and treating them as the same claim overstates what current products have actually been shown to be.
Regulatory Status
Sermorelin is no longer sold as an FDA-approved drug. Geref was discontinued commercially, and Sermorelin is not currently prescribed the way it once was. What's sold under the Sermorelin name today is a research chemical, which is a materially different regulatory category than the approved pharmaceutical it descends from, even though the underlying molecule is the same one that went through FDA review.
Bloodwork to Track
IGF-1 is the standard marker for tracking growth-hormone-axis activity, since it reflects downstream growth hormone output rather than the brief pulse triggered by a single dose. See the IGF-1 blood test explained for what the test measures and how to read it, and the peptide bloodwork guide for how it fits into a broader baseline panel.
Related Reading
For dosing and protocol context, see the Sermorelin compound page. If you're weighing Sermorelin against a related GHRH-pathway peptide, see Ipamorelin vs Sermorelin. BioStackIQ's Rate My Stack and Build Protocol can help you think through where a compound with this evidence profile fits into a broader stack.